Deals channel feed

Habib Dable, Acceleron CEO

In­side the deal: As leaked de­tails goosed its stock, Ac­celeron's CEO pumped Mer­ck for more cash

As leaked details of its potential merger with Merck were splashed across the internet, Acceleron behind the scenes used newfound interest from investors and a last-minute Hail Mary from an unnamed suitor to ply the drug giant for an even more pricey buyout, according to a play-by-play of the deal in an SEC filing.

After weeks of negotiation, Merck late last month agreed to acquire Acceleron and its lead rare cardiovascular disease drug sotatercept for $11.5 billion, confirming days of leaked details on the companies’ negotiations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.

Eric Ostertag, Poseida CEO

Take­da en­lists Po­sei­da in $3.6B+ non­vi­ral gene ther­a­py deal, though da­ta re­main years away from hu­man stud­ies

Takeda has been behind other major players in terms of cell and gene therapy development, but after announcing a collaboration with Selecta Biosciences last week, it’s now on a bit of a spending spree.

The Big Pharma has recruited Poseida Therapeutics to develop in vivo gene therapies in six different indications, the companies announced Tuesday, with Takeda retaining an option to ask for two more. Poseida will get a $45 million upfront payment in the deal, $125 million in short-term preclinical milestones and up to $435 million in clinical milestones per program.

Ace­to keeps up spend­ing spree with ac­qui­si­tion of Ire­land's A&C

Last April, when Aceto acquired Bioreagent, CEO Gilles Cottier wasn’t able to greet any of his new colleagues in person. But Tuesday, 18 months and four acquisitions later, he was in Ireland, meeting members of the A&C Bio Buffer, just as his company announced it bought out the CMO.

The New York-based manufacturer acquired A&C Bio Buffer to help boost its Covid-19 relief efforts and expand its wingspan within manufacturing, the company announced Tuesday.

Jack Khattar, Supernus CEO

Su­per­nus ex­pands its port­fo­lio of Parkin­son's drugs with a $400M+ buy­out

Supernus is marking its expansion into the Parkinson’s disease arena, striking a deal to buy out Adamas Pharmaceuticals in a deal worth more than $400 million.

A year after swooping in on its first Parkinson’s acquisition, the two companies announced that they had reached an agreement for Supernus to pay up to $9.10 per share in cash as part of the acquisition — close to $450 million.

Dave Stack, Pacira BioSciences CEO

Flex­ion heads to the dis­count aisle for a $450M+ merg­er with Paci­ra

Once riding high with its non-opioid drug for knee pain, Flexion was at the center of the M&A rumor mill for a 10-figure buyout. Years later, that shine has worn off — and now Flexion will hand over the keys in a significantly smaller acquisition.

Pacira BioSciences will acquire Flexion for $8.50 per share in a deal valued at $450 million, a steep discount for a biotech that once commanded attention from the likes of drug giant Sanofi, the companies said Monday.

Lumen Bioscience co-founders Jim Roberts (left) and Brian Finrow

Lu­men lands an­oth­er DoD con­tract to treat Covid-re­lat­ed GI is­sues

The team at Lumen Bioscience believes that it can help patients, including those infected with Covid-19, through its plant-based drug LMN-301. Wednesday, it announced that the US Army is a believer too, handing the company development funding for its monoclonal antibody cocktail.

This deal builds on a previous grant from the US Army that helped fund preclinical development of the candidate to treat and prevent the gastrointestinal symptoms of Covid-19, which often takes a back seat to the concerns surrounding respiratory issues. A study out of Wuhan found that GI symptoms were found in 85% of severely ill Covid-19 patients, and 79% in stable patients.

Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)

As con­ti­nen­t's vac­ci­na­tion rate sits be­low 5%, Mod­er­na an­nounces in­vest­ment in mR­NA man­u­fac­tur­ing in Africa

After mounting pressure from competitors, Moderna has signed on to invest $500 million in an mRNA manufacturing site in Africa that could make up to 500 million doses a year.

It’s a move into a region that has been largely neglected historically by Big Pharma, a trend that’s held strong throughout the Covid-19 pandemic. The Moroccan government recently dropped $500 million into a new Recipharm fill-finish plant, and Grifols is building an IV bag plant in Nigeria, but those projects aren’t set to be up and running until 2023 and 2024, respectively.

David Coman, Science 37 CEO

Sci­ence 37 takes the SPAC short­cut to Nas­daq, land­ing a $235M wind­fall for its push on de­cen­tral­ized tri­als

Science 37, which bills itself as a pioneer in the move to decentralized clinical trials, has reached the end of the SPAC trail to Nasdaq.

The life sci company has completed its merger with LifeSci Acquisition II Corp., a blank check company, that will deliver a $235 million bonus of cash, less the usual slate of fees.

Decentralized trials have been all the rage in biopharma, particularly during the pandemic as companies adjusted to lockdowns and distancing demands. But they were trendy even before Covid made them absolutely necessary as drug developers looked for new and better ways to attract a diverse set of patients for clinical studies.

Is the biotech boom start­ing to fade? The roar­ing ‘20s starts to look a lit­tle fa­tigued. Plus: Top 5 deals, IPOs, pacts of Q3

Biotech deal cash continued to gush through Q3, but a careful look at the details in aggregate suggests that the rosy tint to the biotech boom has started to lose some of its color.

Once again, deal master Chris Dokomajilar at DealForma has crunched the numbers on all the gauges we use to assess the performance of the biotech sector. And there’s been a distinct cooling of overall activity, particularly around IPOs and venture cash infusions.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Michael Higgins, Voyager interim CEO

Trou­bled Voy­ager’s gene ther­a­py re­launch gets a boost with $630M Pfiz­er deal

It was spring, the pandemic seemed in retreat, patrons were filling Boston’s bars again and, in Cambridge, Voyager Therapeutics was in trouble.

The Third Rock-founded biotech emerged in 2014 as one of the first of the flashy new gene therapy companies, promising one-time treatments for common devastating conditions like Alzheimer’s. It was one of the first to deliver results, too: By 2017, its Parkinson’s treatment had improved motor function in 10 patients.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.